Clinical trials: Functionality
Seasonal Allergic Rhinitis
New Nasal Applicator / New Formulation - User Study
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
- Trial name
- NCT00641979
- Testing
- budesonide
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Burns, Upper Extremity, Burns, Lower Extremity
Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care
Once the victim survived the acute phase, the outcome of wound healing, the scarring, became a major medical issue with complications that may lead to cosmetic and functional sequelae.
- Trial name
- NCT01800981
- Where
- Slovakia
- Volunteers
- 53 people
- Sponsor
- MediWound Ltd
Achondroplasia
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in participants with ACH who…
- Trial name
- NCT05145010
- Testing
- Infigratinib
- Where
- 31 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Asthma
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
- Trial name
- NCT00130351
- Testing
- formoterol
- Where
- 12 sites in United States
- Volunteers
- 155 people
- Sponsor
- Novartis
Achondroplasia
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of…
- Trial name
- PROPEL3 (NCT06164951)
- Testing
- Infigratinib 0.25 mg/kg/day
- Where
- 27 sites in United States, Argentina and 8 more
- Volunteers
- 114 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Feeding Patterns, Feeding; Difficult, Newborn
Neoneur Feeding System Functionality in the Clinic
Prospective data collection using the Neoneur Feeding System to demonstrate device functionality, correlation to historic data, and prepare for a more extensive phase II SBIR trial
- Conditions
- Feeding Patterns, Feeding; Difficult, Newborn, Feeding Disorder Neonatal
- Trial name
- NN200 (NCT05525091)
- Testing
- Feeding Evaluation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neoneur LLC
Cytomegalovirus, Kidney Transplantation
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
This study aims to validate whether Lophius Biosciences Kit T-Track® CMV is suitable to assess the functionality of CMV-specific cell-mediated immunity (CMI) and to determine a protective cut-off value for CMV…
- Conditions
- Cytomegalovirus, Kidney Transplantation, CMV Specific Immune Response
- Trial name
- CMValue (NCT02083042)
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- Lophius Biosciences GmbH
PCOS
Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is characterized by menstrual abnormalities, clinical or biochemical hyperandrogenism, multiple abnormal cysts and…
- Trial name
- NCT01626443
- Testing
- Myo-inositol + D-chiro-inositol + Folic acid, Folic acid
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Lo.Li.Pharma s.r.l
Asthma
Tezepelumab Home Use Study
This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or…
- Trial name
- PATH-HOME (NCT03968978)
- Testing
- Tezepelumab (APFS), Tezepelumab (AI)
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca